Rehoboth Inc

OX2 Therapeutics, Inc., based in Minneapolis, MN, has received FDA approval for a Phase I clinical trial to develop a novel peptide ligand checkpoint inhibitor for patients with central nervous system tumors, specifically high-grade glioblastoma. Their groundbreaking CD200AR-L peptide is designed to target the CD200 immune checkpoint, modulating the immune system to enhance anti-tumor responses and potentially revolutionize cancer therapy. Utilizing innovative technology, OX2 Therapeutics aims to overcome the complex interplay between the immune system and tumor microenvironment by developing a platform that could extend to the treatment of other solid tumors. With promising results in survival studies on both murine models and canine patients, OX2 Therapeutics is at the forefront of advancing immunotherapy to combat cancer and improve patient outcomes.Generated from the website

From the website:Whether it's oboes, bassoons, clarinets, or saxophones, MMI is the shop, rental, and repair resource for instruments and instrument accessories. Learn more